Japanese Pharma to 2010 - Imminent Transition Towards Globalization Necessary for Survival

Introduction

Dominated by domestic companies in the past, the Japanese pharmaceutical market is evolving, as regulatory changes stimulate direct western competition and generic penetration, and government cost containment measures restrict the market. The Japanese pharmaceutical companies must focus on rejuvenating their product offerings and strengthening their pipelines to drive global growth.

Scope

• Profiles of 15 Japanese pharma companies, providing analysis of the companies’ strategy, portfolio and pipeline and 7-year forecasts for key products
• Benchmarking of top players through strategic, portfolio and financial measures; interactive Comparator and Virtual Merger tools available separately
• Identification of R&D opportunities in the biotechnology industry for Japanese and western players to meet the growing generic threat
• Evaluation of the strategic options available for Japanese players to drive global expansion and western pharmas to increase penetration of Japan

Highlights

Japanese companies must focus on R&D due to the weakness of their mature portfolios, which are at risk of generic penetration. In 2003, 60.8% of the leading Japanese companies’ revenues came from drugs that were more than 10 years old.

Overseas companies must consider their therapeutic focus and marketing capabilities to choose the best growth strategy in Japan. Although recent changes have made it easier for western companies to launch their own products in Japan, many still choose to either out-license products or to co-promote/co-market them.

Although Takeda is forecast to maintain its leadership among the top Japanese pharmas, the creation of Astellas will jeopardize its position by 2010, unless measures are taken by the company to innovate its product portfolio and adopt more aggressive expansion strategies.

Reasons to Purchase

• Optimize your growth strategy in Japan through detailed knowledge of the performance of the leading Japanese pharmas, and local operating conditions
• Identify the best product sourcing strategy for your company’s position
• Benchmark your performance against the leading Japanese pharmas